NVUS Novus Therapeutics, Inc. gains 18% Mar 22, 2018

Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate is galeterone, an oral small molecule that is in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer. The company's androgen receptor degradation agents drug discovery program is focused on identifying and developing compounds for patients with androgen receptor signaling diseases, including prostate cancer. Tokai Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Boston, Massachusetts. http://www.priceseries.com/trade/NVUS-Novus-Therapeutics-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2018031220180322.html